Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of ABBV-CLS-7262 with Rosuvastatin and Digoxin
NCT05763459Phase 1Completed
- Sponsor
- Calico Life Sciences
- Start
- Mar 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fosigotifator in leukoencephalopathy with vanishing white matter (VWM) and amyotrophic lateral sclerosis (ALS), sponsored by Calico Life Sciences. Primary endpoints: Pharmacokinetics of Rosuvastatin at 2 weeks and Pharmacokinetics of Digoxin at 2 weeks. Started Mar 2023; status: completed.
02
Drugs
fosigotifator
03
Conditions
leukoencephalopathy with vanishing white matter (VWM)amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05763459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05763459.